D&A at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s D&A?
- Praxis Precision Medicines, Inc. (PRAX) reported D&A of $39K in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s D&A changed year-over-year?
- Praxis Precision Medicines, Inc.'s D&A decreased by 17.0% year-over-year, from $47K to $39K.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s D&A?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s D&A has grown at a -6.3% compound annual growth rate (CAGR), from $182K to $140K.
- What does D&A mean?
- Non-cash accounting charges for the wear and tear or expiration of assets.
- How do you interpret D&A?
- Higher values indicate significant capital investment in fixed assets or intangible property.
- How does D&A compare across companies?
- Common in capital-intensive industries; lower in early-stage biotech firms with fewer physical assets.